孟鲁司特联合氨溴索雾化治疗儿童支气管哮喘临床观察

Effect of Montelukast Combined with Ambroxol on Bronchial Asthma among Children

目的分析孟鲁司特与氨溴索雾化联合治疗儿童支气管哮喘的效果及对免疫功能、不良反应的影响。方法选择2017年1月—2018年3月诊治的96例支气管哮喘患儿,随机分成研究组(48例)与对照组(48例),对照组予以氨溴索雾化治疗,研究组采用氨溴索雾化联合孟鲁司特治疗,比较两组临床疗效。结果研究组症状缓解时间(2. 03±0. 54) d、再次发作例次(11. 43±3. 06)、持续发作时间(3. 24±1. 03) d均少于对照组(均P <0. 05);研究组FEV1(3. 38±0. 64) L、FVC(3. 96±0. 84) L、FEV1/FVC(84. 63±6. 07)%均优于对照组(均P <0. 05);研究组IL-6(3. 72±1. 12)μg/L、IL-10(4. 43±1. 26)μg/L、TNF-α(3. 40±1. 71)μg/L均优于对照组(均P <0. 05);两组患者出现不良反应的概率无统计学差异(P> 0. 05)。结论儿童支气管哮喘应用孟鲁司特联合氨溴索雾化治疗疗效显著,可有效改善临床症状与肺功能,提升免疫功能,且安全性高。

Objective To analyze the efficacy of Montelukast combined with ambroxol in the treatment of bronchial asthma in children and its effects on immune function and adverse reactions. Methods Ninety-six children with bronchial asthma diagnosed in our hospital from January 2017 to March 1818 were randomly divided into study group （ n =48） and control group （ n =48）. The control group received ambroxol atomization treatment. The study group was treated with ambroxol atomization combined with Montelukast, and then the clinical efficacy of the two groups was compared. Results The duration of symptom relief （2.03±0.54）d, recurrence （11.43±3.06）, and duration of episode （3.24±1.03）d in the study group were lower than those in the control group （ P 〈0.05）. FEV 1 （3.38±0.64）L, FVC （3.96±0.84）L and FEV 1/FVC （84.63±6.07）% in the study group were better than the control group （ P 〈0.05）. IL-6 （3.72±1.12）μg/L, IL-10（4.43±1.26）μg/L, TNF-α（3.40±1.71）μg/L in the study group were better than the control group （ P 〈0.05）. There was no significant difference in the probability of adverse reactions between the two groups （ P 〉0.05）. Conclusion The application of Montelukast combined with ambroxol in children with bronchial asthma is effective and safe, which can effectively improve clinical symptoms and lung function and enhance immune function.